These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8239299)

  • 1. Selective signaling via unique M1 muscarinic agonists.
    Fisher A; Heldman E; Gurwitz D; Haring R; Barak D; Meshulam H; Marciano D; Brandeis R; Pittel Z; Segal M
    Ann N Y Acad Sci; 1993 Sep; 695():300-3. PubMed ID: 8239299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in medicinal chemistry of novel selective muscarinic agonists.
    Fisher A; Karton Y; Heldman E; Gurwitz D; Haring R; Meshulam H; Brandeis R; Pittel Z; Segall Y; Marciano D
    Drug Des Discov; 1993; 9(3-4):221-35. PubMed ID: 8400004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update.
    Fisher A; Heldman E; Gurwitz D; Haring R; Karton Y; Meshulam H; Pittel Z; Marciano D; Brandeis R; Sadot E; Barg Y; Pinkas-Kramarski R; Vogel Z; Ginzburg I; Treves TA; Verchovsky R; Klimowsky S; Korczyn AD
    Ann N Y Acad Sci; 1996 Jan; 777():189-96. PubMed ID: 8624083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease.
    Fisher A; Brandeis R; Karton I; Pittel Z; Gurwitz D; Haring R; Sapir M; Levy A; Heldman E
    J Pharmacol Exp Ther; 1991 Apr; 257(1):392-403. PubMed ID: 2019998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives.
    Fisher A; Michaelson DM; Brandeis R; Haring R; Chapman S; Pittel Z
    Ann N Y Acad Sci; 2000; 920():315-20. PubMed ID: 11193170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
    Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
    J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AF102B, a muscarinic M1 receptor agonist, mimics some effects of acetylcholine on neurons of rat hippocampus slices.
    Segal M; Fisher A
    Eur J Pharmacol; 1992 Sep; 220(1):103-6. PubMed ID: 1425975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
    Fisher A; Pittel Z; Haring R; Bar-Ner N; Kliger-Spatz M; Natan N; Egozi I; Sonego H; Marcovitch I; Brandeis R
    J Mol Neurosci; 2003; 20(3):349-56. PubMed ID: 14501019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.
    Fisher A
    Jpn J Pharmacol; 2000 Oct; 84(2):101-12. PubMed ID: 11128032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.
    Langmead CJ; Austin NE; Branch CL; Brown JT; Buchanan KA; Davies CH; Forbes IT; Fry VA; Hagan JJ; Herdon HJ; Jones GA; Jeggo R; Kew JN; Mazzali A; Melarange R; Patel N; Pardoe J; Randall AD; Roberts C; Roopun A; Starr KR; Teriakidis A; Wood MD; Whittington M; Wu Z; Watson J
    Br J Pharmacol; 2008 Jul; 154(5):1104-15. PubMed ID: 18454168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: an unifying hypothesis.
    Fisher A; Brandeis R; Haring R; Eshhar N; Heldman E; Karton Y; Eisenberg O; Meshulam H; Marciano D; Bar-Ner N; Pittel Z
    J Physiol Paris; 1998; 92(5-6):337-40. PubMed ID: 9789833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands.
    Gurwitz D; Haring R; Heldman E; Fraser CM; Manor D; Fisher A
    Eur J Pharmacol; 1994 Mar; 267(1):21-31. PubMed ID: 8206127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NGF promotes amyloid precursor protein secretion via muscarinic receptor activation.
    Haring R; Gurwitz D; Barg J; Pinkas-Kramarski R; Heldman E; Pittel Z; Danenberg HD; Wengier A; Meshulam H; Marciano D
    Biochem Biophys Res Commun; 1995 Aug; 213(1):15-23. PubMed ID: 7639729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update.
    Fisher A
    Curr Alzheimer Res; 2007 Dec; 4(5):577-80. PubMed ID: 18220527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102B.
    Haring R; Gurwitz D; Barg J; Pinkas-Kramarski R; Heldman E; Pittel Z; Wengier A; Meshulam H; Marciano D; Karton Y
    Biochem Biophys Res Commun; 1994 Aug; 203(1):652-8. PubMed ID: 8074717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of muscarinic agonists for successful therapy of Alzheimer's disease.
    Fisher A; Brandeis R; Haring R; Bar-Ner N; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
    J Neural Transm Suppl; 2002; (62):189-202. PubMed ID: 12456063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
    Dunbar PG; Durant GJ; Rho T; Ojo B; Huzl JJ; Smith DA; el-Assadi AA; Sbeih S; Ngur DO; Periyasamy S
    J Med Chem; 1994 Aug; 37(17):2774-82. PubMed ID: 8064804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.
    Lazareno S; Popham A; Birdsall NJ
    J Mol Neurosci; 2002; 19(1-2):123-7. PubMed ID: 12212769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors.
    Fisher A
    Neurodegener Dis; 2008; 5(3-4):237-40. PubMed ID: 18322400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and SAR of bulky 1-azabicyclo[2.2.1]-3-one oximes as muscarinic receptor subtype selective agonists.
    Tecle H; Lauffer DJ; Mirzadegan T; Moos WH; Moreland DW; Pavia MR; Schwarz RD; Davis RE
    Life Sci; 1993; 52(5-6):505-11. PubMed ID: 8382765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.